Table 3.
Characteristics of included articles.
| Arthur | Year | Experiment design | Golden standard | Geographical distribution of strains | Source of samples | Total sample | Genotype | Total | Events | Detection rate |
|---|---|---|---|---|---|---|---|---|---|---|
| Tato [9] | 2016 | prospective | culture and sequence | UK | 383 clinical isolates and 250 contrived isolates | 633 | OXA-48 | 40 | 38 | 95% |
| NDM | 26 | 26 | 100% | |||||||
| VIM | 31 | 29 | 93.55% | |||||||
| KPC | 30 | 29 | 96.67% | |||||||
| IMP | 27 | 26 | 96.30% | |||||||
|
| ||||||||||
| McMullen [10] | 2017 | retrospective | laboratory-developed PCR assays or must have been previously characterized as part of the CDC | USA, UK and Spain | 189 clinical isolates | 189 | OXA-48 | 12 | 12 | 100% |
| NDM | 27 | 27 | 100% | |||||||
| VIM | 7 | 7 | 100% | |||||||
| KPC | 84 | 84 | 100% | |||||||
| IMP | 1 | 1 | 100% | |||||||
|
| ||||||||||
| Moore [11] | 2017 | prospective | culture and sequence | France | 755 clinical isolates and 432 contrived isolates | 1187 | OXA-48 | 113 | 111 | 98.23% |
| NDM | 88 | 88 | 100% | |||||||
| VIM | 92 | 87 | 94.57% | |||||||
| KPC | 110 | 110 | 100% | |||||||
| IMP | 80 | 76 | 95% | |||||||
|
| ||||||||||
| Findlay [14] | 2015 | retrospective | in-house PCR | UK | 450 isolates cultured from 2808C freezer storage or from the sender's original slopes on MacConkey agar plates with a 10 mg ertapenem disc | 450 | OXA-48 | 100 | 100 | 100% |
| NDM | 100 | 100 | 100% | |||||||
| VIM | 100 | 100 | 100% | |||||||
| KPC | 100 | 100 | 100% | |||||||
| IMP | 24 | 17 | 71% | |||||||
|
| ||||||||||
| Hoyos-Mallecot [15] | 2017 | retrospective | culture and sequence | USA and Italy | 241 clinical isolates | 241 | KPC | 1 | 1 | 100.00% |
| OXA-48 | 10 | 10 | 100% | |||||||
|
| ||||||||||
| Kost [16] | 2017 | retrospective | determined by PCR or whole genome sequencing | USA and Europe | 96 clinical isolates | 96 | OXA-48 | 9 | 8 | 88.90% |
| NDM | 25 | 25 | 100% | |||||||
| VIM | 3 | 3 | 100% | |||||||
| KPC | 43 | 41 | 95.30% | |||||||
| IMP | 2 | 2 | 100% | |||||||
|
| ||||||||||
| Vanstone [17] | 2018 | retrospective | in-house antimicrobial susceptibility testing(AST) | USA | 26 clinical isolates and 69 screening samples | 95 | OXA-48 | 24 | 24 | 100% |
| NDM | 22 | 22 | 100% | |||||||
| VIM | 19 | 19 | 100% | |||||||
| KPC | 3 | 3 | 100% | |||||||
| IMP | 1 | 1 | 100% | |||||||
|
| ||||||||||
| Traczewski [18] | 2018 | retrospective | culture and sequence | USA | 428 clinical isolates and 57 fresh isolates | 485 | OXA-48 | 89 | 89 | 100% |
| NDM | 78 | 78 | 100% | |||||||
| VIM | 82 | 82 | 100% | |||||||
| KPC | 84 | 84 | 100% | |||||||
| IMP | 40 | 40 | 100% | |||||||
|
| ||||||||||
| Cointe [19] | 2019 | prospective | PCR | France | 53 clinical isolates | 53 | OXA-48 | 10 | 10 | 100% |
| NDM | 11 | 11 | 100% | |||||||
| VIM | 7 | 7 | 100% | |||||||
| KPC | 10 | 10 | 100% | |||||||
| IMP | 1 | 1 | 100% | |||||||